Biogen (BIIB) option implied volatility low into decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE

Biogen (NASDAQ: BIIB) March weekly and April call option implied volatility is at 27 compared to its 52-week range of 21 to 45 into the company and partner Eisai (ESALY) announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE.

You May Also Be Interested In

• Schlumberger (SLB) option IV elevated into quarter results and outlook
• Fifth Third Bancorp (FITB) April 34 puts active into quarter results and outlook
• Huntington Bancshares (HBAN) April option implied volatility into quarter results